Biotechnology

Moleculin Biotech

Moleculin Biotech released FY2026 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -3.5422 (forecast USD -1.6633)

Moleculin Biotech released FY2025 annual earnings on March 18 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -28.4187 (forecast USD -36.35)

Moleculin Biotech released FY2025 Q4 earnings on March 18 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD 6.8995 (forecast USD -6.1133)

H.C. Wainwright reiterates buy rating on Moleculin Biotech

Moleculin Biotech released FY2025 Q3 earnings on November 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -17.0214 (forecast USD -6.5833)

Moleculin Biotech released FY2025 9 Months Earnings on November 13, 2025 (EST) with actual revenue of USD 0 and EPS of USD -60.0969

Moleculin Biotech Enters into Research Agreement with UNC Chapel Hill for Annamycin Pancreatic Cancer Therapy

Moleculin Biotech Obtains Annamycin Patent in Australia

Moleculin Biotech Launches Annamycin Clinical Trial for Late-Stage Pancreatic Cancer

Moleculin Biotech Receives Patent Allowance Notice for Liposomal Annamycin

Moleculin Biotech released FY2025 Semi-Annual Earnings on August 12 (EST), actual revenue USD 0, actual EPS USD -46.0352

Moleculin Biotech released FY2025 Q2 earnings on August 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.0911 (forecast USD -0.4033)

Moleculin Biotech Signs $6.5 Million Market Offering Agreement

Moleculin Biotech Expands AML Clinical Trial Sites

Moleculin Biotech Receives Nasdaq Delisting Warning

Moleculin Biotech CEO Buys Company Stock

Moleculin Biotech Files for Public Offering with Warrants

HC Wainwright Reiterates Buy Rating on Moleculin Biotech

Moleculin Biotech's Cancer Drug Annamycin Receives Positive FDA Feedback and Approval

Moleculin Biotech Annamycin Trial Fails to Reach Complete Remission, Stock Dips

CCSC Tech

Youlife

Core AI

Regentis Biomaterials

Epsium Enterprise

Autozi Internet Tech Global

Leslies

Mega Matrix

eLong Power

Smart Logistics Global

MBRX

Moleculin Biotech reported independent research indicating strong interest in Annamycin for relapsed/refractory AML. Oncologists gave a 6/7 likelihood-to-prescribe score, driven by complete remissions, MRD-negative responses, and transplant-bridging potential. Key advantages include biomarker-agnostic applicability, combination therapy potential, and reduced cardiotoxicity allowing repeat dosing. Payers and administrators view it as a compelling value proposition for broad patient populations.

TradingView

Moleculin market study shows strong physician, payer interest in Annamycin for R/R AML

Moleculin Biotech announced independent market research showing strong physician intent to prescribe Annamycin for relapsed/refractory AML, with an average likelihood-to-prescribe score of 6 out of 7. Key drivers include deep remissions, transplant-bridging potential, biomarker-agnostic use, and reduced cardiotoxicity. Payers also view the drug as a meaningful value proposition due to its efficacy and safety profile in addressing significant unmet needs.

StockTitan

Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML | MBRX Stock News

Moleculin Biotech CEO Walter Klemp discussed the enrollment of the 45th subject in the pivotal Phase 2B/3 MIRACLE trial for Annamycin in R/R AML during a Virtual Investor segment. This milestone triggers final preparations for interim data unblinding, expected mid-2026, marking a potential inflection point for the company.

Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment | MBRX Stock News

LABU

SBIO

Moleculin Biotech presented ASCO 2026 data showing Annamycin had no detectable cardiotoxicity despite exposure levels far exceeding conventional anthracycline limits. An independent Cleveland Clinic review supported these safety findings in a pooled analysis of 90 patients. The company highlighted that this differentiated cardiac profile strengthens the rationale for its ongoing Phase 2b/3 MIRACLE trial for relapsed/refractory AML, with unblinding expected in June 2026.

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

VanEck Biotech ETF

Direxion S&P Biotech Bear 3X

iShares Biotechnology ETF

Proshares UltraShort Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits | MBRX Stock News

Moleculin announced the acceptance of a poster at ASCO 2026, presenting pooled cardiac safety data for Annamycin, indicating no drug-induced cardiotoxicity. The independent review involved 90 patients, with a median Annamycin dose of 660 mg/m2. No significant changes in LVEF were observed, and serial ECGs and biomarkers supported the findings, reinforcing the rationale for the MIRACLE trial.

Moleculin poster acceptance at ASCO shows pooled Annamycin cardiac safety across 90 patients

Moleculin Biotech, Inc. announced that an abstract on cardiac safety data for its drug Annamycin has been accepted for poster presentation at the 2026 ASCO Annual Meeting. The study shows no significant change in left ventricular ejection fraction among patients treated with Annamycin, indicating a differentiated safety profile. The findings support ongoing trials for Annamycin in treating acute myeloid leukemia and soft tissue sarcoma, aiming to provide effective therapy without traditional cardiotoxicity limitations.

Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin | MBRX Stock News

Preliminary data from the MIRACLE Trial reveals an impressive 40% overall complete remission rate in a challenging group of AML patients. This trial, which includes a diverse patient population, is showing promising results.

Unusual Whales

Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial

Moleculin Biotech(MBRX.US)